Imagion Biosystems Limited (Company) is committed to the objective of promoting investor confidence and the rights of shareholders.
Read the Imagion Biosystems Limited Disclosure and Communication Policy.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)